News

NewAmsterdam Pharma's Insights at the Virtual Cardiometabolic Forum

NewAmsterdam Pharma's Insights at the Virtual Cardiometabolic Forum

NewAmsterdam Pharma's Upcoming Presentation

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is gearing up for an exciting participation at the renowned Stifel 2025 Virtual Cardiometabolic Forum. The company, well-regarded for its late-stage development of oral non-statin medicines for cardiovascular disease (CVD), is set to feature prominently in discussions aimed at improving patient care and addressing significant medical needs.

Engagement of Key Executives

During the forum, scheduled for a future date, the spotlight will be on John Kastelein, the Chief Scientific Officer, and Matthew Philippe, the Executive Vice President, who will engage the audience in a virtual fireside chat. Their insights are expected to provide valuable perspectives on the innovative work being done at NewAmsterdam, specifically in the realm of treating patients with elevated low-density lipoprotein cholesterol (LDL-C).

Live Webcast Experience

For those interested in learning more about NewAmsterdam's advancements, the company will make a live webcast available through their investor relations section. Following the chat, an archived replay can also be accessed on their official website, ensuring broader reach and engagement with stakeholders and the public alike.

The Mission of NewAmsterdam Pharma

At the heart of NewAmsterdam's mission lies a commitment to enhance patient lives, particularly in populations battling metabolic diseases where existing therapies have fallen short. The company aims to provide a safe, well-tolerated, and practical LDL-lowering therapy, addressing a significant gap in treatment options currently available.

Clinical Trials and Innovations

In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose CETP inhibitor aimed at reducing LDL-C levels among those at risk of CVD. This treatment is being studied both individually and as a fixed-dose combination with ezetimibe, offering promising results for patients who are not achieving desired outcomes with existing therapies.

Company Contact Information

For inquiries, Matthew Philippe is available at 1-917-882-7512 or via email at matthew.philippe@newamsterdampharma.com. Interested parties can also reach out to the media contact, Christian Edgington at Real Chemistry, at 1-513-310-6410 or at cedgington@realchemistry.com.

Frequently Asked Questions

What is the focus of NewAmsterdam Pharma?

NewAmsterdam Pharma focuses on developing innovative oral medications for lowering cholesterol in patients at risk of cardiovascular disease.

Who will be speaking at the Stifel 2025 Virtual Cardiometabolic Forum?

John Kastelein, Chief Scientific Officer, and Matthew Philippe, Executive Vice President, will represent NewAmsterdam Pharma during the event.

How can I watch the live presentation?

The presentation will be available via a live webcast through the investor relations section of NewAmsterdam's official website.

What is obicetrapib?

Obicetrapib is an experimental therapy being investigated by NewAmsterdam as a treatment option for lowering LDL cholesterol in patients with cardiovascular risks.

How can I contact NewAmsterdam Pharma?

You can contact Matthew Philippe at 1-917-882-7512 or via email at matthew.philippe@newamsterdampharma.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ensuring Your Radon Mitigation System Stays Effective

Updated Category News Views 2

Radon Mitigation: A Critical Measure for Home Safety Homeowners, you're probably aware of the ticking health time bomb known as radon. Not just an annoying gas, this colorless, odorless beast lurks quietly, threatening family health if not managed right. Mitch Kelley, a specialist in radon testing with Basement Solutions in Mankato, Minnesota, lays out a no-fuss guide to...

Continue Reading
Bellissima Bags Allure Award for Curly Hair Tool

Updated Category News Views 4

Award-Winning Tool Headlines 2026 Beauty Scene There's a shake-up in the world of hair tools, folks. Bellissima's Diffon Supreme has snagged a 2026 Allure Best of Beauty Award for its prowess in taming the curly, wavy, and coily strands we all crave to manage. Performance Meets Innovation in Bellissima's Latest Let's not beat around the bush. The Diffon Supreme's trump...

Continue Reading
Crimson Coward's Cheez Nugs Shake Up Fast-Casual Scene

Updated Category News Views 7

New Kid on the Block: Cheez Nugs Buckle up folks, Crimson Coward is at it again. They're rolling out something they claim will blow your taste buds straight out of the water: Cheez Nugs. Dropping nationwide on September 18, 2026, these aren't your run-of-the-mill cheese bites. We're talking 100% whole-milk mozzarella, a golden herb-seasoned crust, and a mouthful of creamy...

Continue Reading
AI Agents Challenge Product Governance Models

Updated Category News Views 6

AI's Increasing Role: A Double-Edged Sword for Leaders Hey, the tech overlords remind us once again—the future doesn't wait for anyone to catch up before it bulldozes forward. Info-Tech Research Group has sounded the alarm on AI agents muscling their way into product decisions without any clear nod from the human corner office. Blurring Lines of Accountability The...

Continue Reading
Mental Health Day Celebrations Set for October in NYC

Updated Category News Views 7

Mental Health Steals the October Spotlight In the bustling streets of New York City, October is about to get a mental health makeover. Project Healthy Minds is putting the pedal to the metal with their fourth annual World Mental Health Day Gala on October 8th, followed by the world’s largest mental health festival on October 10th. These events, held at Spring Studios,...

Continue Reading
ETERC's Ele Aims to Revolutionize STEM Education for All

Updated Category News Views 6

The AI Mentor Battleground in Education Ever found yourself wondering how public schools could step up their game without dumping money down the tech rabbit hole? ETERC’s latest push with Ele may just be a game-changer for them. We're not talking about your run-of-the-mill chatbot regurgitating facts from the internet—this is an AI tricked out for personalized...

Continue Reading
Debt Crisis Looms: Social Security at Risk

Updated Category News Views 4

Debt Reality: A National Concern with Global Implications When it comes to the U.S. federal debt situation, the latest report from the National Seniors Policy Center is lighting a fire like no other, warning us that we're not crying wolf here. We've got fiscal numbers that may not sit well at breakfast. With roughly 67 cents of every new buck Uncle Sam borrows going to...

Continue Reading
California Accelerates AI Law with Newsom's Bold Move

Updated Category News Views 3

Pushing AI Regulations into High Gear I'll tell you what—it's about time somebody shook things up in the AI world with more than empty promises. Governor Newsom's executive order is doing just that, fast-tracking the timeline for implementing California's SB 813. This move is like giving speed boots to the legislative process, revving up the rules to ensure AI doesn't...

Continue Reading
IRS Views Challenge Tax-Engineered Healthcare Schemes

Updated Category News Views 4

Nonprofit Models Shine Amid IRS Scrutiny Out in Oxnard, California, there's a brewing storm in the healthcare sector. No, it's not a billing error or yet another scandal. We're talking about a seismic shift that could poke holes in those tax-engineered Section 105(b) programs, all thanks to some hard-hitting IRS memoranda. The Nonprofit–TPA Model: A Safer Bet? Enter...

Continue Reading
Debbie's Dream Foundation Launches 2026 Youth Art Contest

Updated Category News Views 5

Young Artists Called to Inspire a Cancer-Free World What's the first image that pops into your head when you think of a world free from cancer? That's the magic question on deck for this year's Youth Art Contest by Debbie's Dream Foundation. Imaginations are set to run wild as the competition opens its gates to artists under 18, calling for visions splashed across...

Continue Reading

Top 5 Most Recently Viewed Articles

Dynacor Group Announces Monthly Dividend Payment for Shareholders

Updated Category News Views 143

Dynacor Group Declares Monthly Dividend Payments DYNACOR GROUP INC. (TSX: DNG) has announced a dividend payment for its shareholders that reflects the company's commitment to rewarding its investors. For the upcoming month, the company will distribute a dividend of C$0.01333 per common share, illustrating a steady financial approach. Dividend Details and Eligibility The...

Continue Reading
Cereno Scientific Expands CS014 Focus to Combat PH-ILD

Updated Category News Views 102

Cereno Scientific Expands CS014 Focus to Combat PH-ILD Cereno Scientific, a pioneering biotech company, has made a significant announcement regarding the development focus of its HDAC inhibitor CS014. This innovative treatment is now targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD), an area marked by a high level of unmet medical need....

Continue Reading
Enlight Launches Tapolca Solar Facility, Boosting Capacity in Hungary

Updated Category News Views 204

Enlight Announces the Start of Commercial Operations at the Tapolca Solar Project The Tapolca solar project features an impressive capacity of 60 MW, with a total investment of $48 million dedicated to its construction. This project marks Enlight's fifth initiative in Hungary, boosting the Company's total operational generation capacity in the country to 144 MW. TEL AVIV,...

Continue Reading
Swvl Expands Its Operations into Europe with SaaS Contract

Updated Category News Views 183

Swvl's Entry into the European Market with SaaS Swvl is thrilled to announce its expansion into the European market with the launch of its Software as a Service (SaaS) offerings in the United Kingdom. This significant milestone not only marks Swvl's first enterprise contract in Europe but also indicates the Company’s strategic direction in adapting its revolutionary...

Continue Reading
NewAmsterdam Pharma's Insights at the Virtual Cardiometabolic Forum

Updated Category News Views 102

NewAmsterdam Pharma's Upcoming Presentation NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is gearing up for an exciting participation at the renowned Stifel 2025 Virtual Cardiometabolic Forum. The company, well-regarded for its late-stage development of oral non-statin medicines for cardiovascular disease (CVD), is set to feature prominently in discussions aimed at...

Continue Reading